UMedic which got itself listed on the Ace Market in July 2022, is seeking to undertake the proposed transfer of the listing of and quotation for the entire issued share capital from the ACE Market to the Main Market of Bursa Malaysia Securities Berhad.
The group has announced that it has met all the conditions necessary for the transfer after achieving an audited consolidated profit after taxation attributable to owners of the parent of approximately RM10.32 million for the most recent financial year
ended 31 July (“FYE”) 2023 and an aggregate combined/consolidated PAT of approximately RM21.83 million for the past three (3) FYEs 2021 to 2023.
In considering whether the profit requirements of the Equity Guidelines were met, the audited combined/consolidated PAT was adjusted for other income for the respective FYEs which were non-recurring in nature and/or not being in the ordinary course of UMC Group’s businesses; and listing expenses which were non-recurring.
